Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2023 Earnings Call Transcript

Rick Winningham: So I’ll start with it, and then I’ll hand it over to Rick. I think relative to the disclosure and what a release might look like, we’re still working through that, obviously, with our partner being able to show a difference — clinically meaningful difference in FEV1 along the range that we saw in earlier GOLD 3, GOLD 4 patients that Rick highlighted that would be quite substantial. And we can talk about the secondaries, but we’re still working through — talking about secondaries. We’re still working through what the disclosure would be in a release. Rick?

Rick Graham: Yes, not much more to add. But Eva I think as Rick said, the primary endpoint change from baseline in trough FEV1 at the key secondary endpoint, trough overall treatment effect on FEV1, I think that’s probably reasonable to include. And then key focus on the key safety events. And then as we usually do after top line, we’ll present the follow-up data in some form perhaps an upcoming medical meeting.

Eva Xia Privitera: Perfect. Thank you so much.

Operator: Thank you. This does conclude the question-and-answer session of today’s program. I’d like to hand the program back to Rick Winningham for any further remarks.

Rick Winningham: Yes, I’d just like to thank you for joining us today for a discussion on the second quarter results. We look forward to keeping you updated through the remainder of the year, and we’re very excited about 2023 and what it means for the company, what it means for our execution and driving our mission to medicines that make a difference for patients and driving long-term shareholder value. So with that, thank you very much, and have a good day.

Operator: Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.